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ABSTRACT 
The purpose of the present study was to investigate the potential cardioprotective effects of 
an original approach based on the properties of the X chromosome-linked Inhibitor of 
Apoptosis (XIAP), the most effective endogenous inhibitor of apoptosis. For this purpose, the 
C-terminal part of XIAP (BIR3 and RING domains) was fused to the protein transduction 
domain (PTD) of the HIV1 transactivator of transcription, which confers to fused protein the 
ability to cross cell membranes. This protein, so-called PTD-BIR3/RING, was administered 
intravenously in C57BL/6J mice subjected to 30 min coronary artery occlusion and 24 h of 
reperfusion. Administration of PTD-BIR3/RING at 5 min before and 30 min after the onset of 
reperfusion reduced infarct size vs control (23±2% vs 41±4% and 27±4% vs 41±3%, 
respectively, p<0.05). Similar reduction in infarct size was observed when PTD-BIR3/RING 
was administered prior to ischemia (28±1% vs 44±3%). In addition to inhibition of caspase-3 
and -9 activities, PTD-BIR3/RING induced an inhibition of caspase-8 and several other actors 
of the apoptotic pathways. In conclusion, this study demonstrates that the administration of 
PTD-BIR3/RING reduces myocardial infarct size even when injected during reperfusion 
through interruption of caspase activation by pharmacologically mimicking endogenous 
XIAP. 
 
Key words: Cardioprotection, infarction, XIAP, reperfusion, caspase activity. 
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INTRODUCTION 
Although the current therapeutic strategy during acute myocardial infarction is to re-
establish coronary blood flow by angioplasty, thrombolysis or cardiac surgery, the associated 
morbidity and mortality remain important and therefore require additional cardioprotection. 
For many years, different approaches such as early and delayed preconditioning (1, 2), 
pharmacological cardioprotection (3-6) or more recently postconditioning, i.e., brief 
interruptions of reperfusion with short episodes of myocardial ischemia (7) have been 
extensively investigated in this regard. Interestingly, clinical studies have demonstrated the 
benefit of ischemic postconditioning in patients with acute myocardial infarction (8-10). 
However, the clinical translation of almost all these strategies is limited by the schedule of 
treatment as they must be applied either before the onset of ischemia or within the very first 
minutes of reperfusion (11-13) and also by the fact that postconditioning is restricted to 
patients who are undergoing percutaneous coronary intervention. Therefore, the development 
of other cardioprotective strategies still remains a major challenge.  
Cell death after ischemia-reperfusion occurs at least by necrosis and apoptosis. Apoptosis 
is a programmed cell death controlled by the death receptor, the mitochondrial pathways 
through caspase activation and also endogenous regulators of apoptotic cell death. In this 
setting, XIAP (X chromosome-linked Inhibitor of Apoptosis) is a major inhibitor of apoptosis 
in cardiomyocyte (14) and ischemia or hypoxia are known to reduce XIAP expression (15, 
16). XIAP possesses three baculovirus IAP repeat (BIR1, BIR2 and BIR3) domains and a 
RING (really interesting new gene) domain. The BIR3 domain interacts with caspase-9 (17) 
while the RING domain possesses a E3 ligase activity and is implicated in proteasome-related 
degradation of a number of substrates that include caspase-3 (18). Among the endogenous 
inhibitors of apoptosis such as IAP1, IAP2, ILP2, MLIAP, NIAP, XIAP is the best 
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characterized of mammalian IAPs and it is also the most potent and versatile of these 
regulators of cell death (19, 20). XIAP mRNA has been observed in all adult and fetal tissues 
examined except peripheral blood leukocytes, indicating that it is an ubiquitous expressed 
member of the IAP family (21). 
Accordingly, the aim of the present study was to examine whether the C-terminal part of 
XIAP (BIR3 and RING domains) fused to the protein transduction domain (PTD) of the TAT-
fusion system (HIV1 transactivator of transcription), i.e., PTD-BIR3/RING, could protect the 
myocardium against infarction. Fusion of BIR3/RING domains with TAT confers to this 
aminoacidic sequence the ability to cross cell membranes with a great efficacy (22), thereby 
decreasing the amount of protein needed for biological efficacy. We hypothesized that a 
beneficial effect could be observed when PTD-BIR3/RING is administered before but also 
during reperfusion, by pharmacologically mimicking the effects of XIAP. In addition, we also 
investigated several proteins that play important roles in the apoptotic transduction signaling 
along with caspase activities. 
  
5 
METHODS 
The experiments were performed in accordance with the official regulations of the French 
Ministry of Agriculture. The authors have been granted a license from the institutional office 
“Préfecture du Val de Marne” (France) to conduct animal research (n° A 94-028-245). 
Generation, production and purification of PTD-BIR3/RING 
A construct encoding the BIR3/RING domains of XIAP was amplified from the cDNA of 
the entire reading frame of rat XIAP and purified fragments were cloned into the XhoI/EcoRI 
sites of the pTAT-HA vector (23). The final cDNA encoded a protein comprising a 6-histidine 
residues tag, the PTD sequence of TAT, a hemagglutinin (HA) tag and BIR3/RING 
sequences. Plasmids, i.e., the PTD-BIR3/RING and PTD-HA alone were expressed in the E. 
coli strain BL21(DE3) pLysS (Stratagene, La Jolla, CA, USA) as previously described (23). 
Protein production was induced by addition of 500 µM isopropyl 1-thio-β-D-galactoside. 
Proteins were extracted in 8M urea HEPES buffer and were purified using a Ni-NTA 
superflow agarose column (Qiagen, Hilden, Germany). Salt was removed using dialysis 
(Pierce Biotechnology Inc, Rockford, IL, USA) and proteins were collected in a solution 
containing phosphate buffered saline. The molecular weight of purified proteins was verified 
by Coomassie blue staining of electrophoresis gels. 
Animal model of myocardial infarction 
Male C57BL6/J mice (6-8 weeks) were anesthetized by intraperitoneal injection of 
pentobarbital sodium (50 mg/kg), intubated and ventilated mechanically. The body 
temperature was measured using a rectal probe and was maintained at 37°C with a blanket 
connected to an homeothermic regulator (Homeo-blanket system 50-7221F, Harvard 
Apparatus, Les Ulis, France). A small catheter was inserted into a jugular vein for 
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administration of the treatment and a thoracotomy was performed. A coronary artery 
occlusion and reperfusion was achieved with an 8-0 Prolene thread placed around the left 
coronary artery as previously described (24). Myocardial ischemia was confirmed by ST 
segment deviation of the electrocardiogram and the occurrence of regional cyanosis. 
Reperfusion was confirmed by visualisation of hyperemic response and the chest was closed 
in layers. 
Experimental protocol 
The experimental protocols are shown in figure 1. To determine the effects of PTD-
BIR3/RING on myocardial infarct size, mice underwent 30 min of coronary artery occlusion 
followed by 24 h of reperfusion. In these experiments, PTD-BIR3/RING (0.8µg/g) was 
injected intravenously either 5 min before ischemia as well as 5 min before and 30 min after 
the onset of reperfusion. The dose of 0.8 µg/g was chosen on the basis of preliminary 
experiments investigating the infarct-limiting effects of increasing doses of PTD-BIR3/RING. 
The control groups were treated with vehicle (phosphate buffer saline) 5 min before ischemia, 
5 min before and 30 min after the onset of reperfusion. Although it would have been more 
appropriate to use PTD-HA in the control mice, it is unlikely that the use of phosphate buffer 
saline represents an experimental biais as we verified that administration of PTD-HA (1 
mg/ml and 0.8 µg/g) alone at 30 min of reperfusion did not elicit proper effects on myocardial 
infarct size (40±4%, n=6 vs 41±3%, n= 9 for PTD-HA and phosphate buffer saline-treated 
mice, respectively). 
Assessment of infarct size 
At the end of the 24 h reperfusion period, the coronary artery was reoccluded at the 
previous site of occlusion. The area at risk was identified by negative Evan’s blue dye 
staining and the infarct area was identified by triphenyltetrazolium chloride (TTC) negative 
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staining. The area
 
at risk was expressed
 
as a percentage of the left ventricle weight. The 
infarcted area
 
was expressed as percentages of the area at risk. 
Histology 
Briefly, formalin-fixed slices of infarcted hearts were embedded in paraffin for histological 
analysis. Five micrometers-thick sections were cut from each paraffin block and stained with 
H&E (Hematoxylin&Eosin). 
Caspase activity assay 
In these experiments, PTD-BIR3/RING (0.8 µg/g) was administered at 30 min of 
reperfusion and proteins were extracted from left ventricles after 1 h, 3 h and 24 h of 
reperfusion and assayed for caspase activity (figure 1). Extraction was also performed in 3 
additional mice that did not undergo ischemia-reperfusion. Tissues were homogenized in cold 
buffer (25mM HEPES pH 7.5, 5mM MgCl
2
, 2mM EDTA, 0.1% Triton X100, 2mM 
dithiothreitol, 1mM PMSF, 5µl/ml protease cocktail inhibitor P8849, Sigma-Aldrich, St 
Louis, MO, USA). Homogenates were centrifuged and supernatants were collected. Proteins 
(50µg) were incubated in caspase assay buffer (50mM HEPES pH 7.4, 100mM NaCl, 1mM 
EDTA, 10mM dithiothreitol). Enzymatic reaction was started by addition of 0.2mM of the 
fluorogenic substrates ac-DEVD-AFC, ac-IETD-AFC, ac-LEHD-AFC (Biomol Research 
Laboratories, Hambourg, Germany) to caspase-3, caspase-8 and caspase-9, respectively. 
Fluorescent arbitrary units were converted into µmoles of AFC/h/mg protein using a standard 
curve of free AFC (Sigma-Aldrich, St Louis, MO, USA).  
Western blot analysis 
In these experiments, PTD-BIR3/RING (0.8 µg/g) was administered at 30 min of reperfusion 
and proteins were extracted from left ventricles after 1 h reperfusion (figure 1). Myocardial 
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samples were placed in medium containing 220mM Mannitol, 70mM Sucrose, 10mM 
HEPES, 1mM EGTA, 1mM PMSF, 5mM NaF, 1mM Na
3
VO
4
, 1mM Na
2
 Glycerol 2-
phosphate, 5µl/ml protease inhibitor cocktail (Sigma-Aldrich, St Louis, MO, USA), pH 7.4 at 
4 °C. The tissue was minced with scissors and homogenized on ice using a Teflon Potter 
homogenizer. The homogenate was centrifuged at 1000g for 5 min to remove cellular debris 
and nuclei. The supernatant was centrifuged for 10 min at 10 000g to obtain the mitochondrial 
pellet. The latter was washed with the same medium and centrifuged at 10 000g for 10 min. 
The resulting mitochondrial pellet was resuspended with medium, frozen and thawed several 
times, and finally sonicated to extract the mitochondrial content. The 10 000g supernatant was 
centrifuged at 17 600g for 30 min. The resulting supernatant was the cytosolic fraction. In 
order to check for the absence of mitochondrial contamination of the cytosolic fraction, we 
verified the absence of citrate synthase activity in the cytosolic samples. 
Proteins were separated on 10-15% SDS-polyacrylamide gels using 40-80µg proteins per 
lane and transferred onto PVDF membranes (Millipore Corporate, Billeria, MA, USA). After 
blocking with 5% dry milk in Tris-buffered saline containing 0.1% Tween-20 (TBS-T), 
membranes were incubated for 1 h at room temperature with the following antibodies: rabbit 
polyclonal anti-phospho-Bad 1:200 (at Ser
136
), rabbit polyclonal anti-Bad 1:250, rabbit 
polyclonal anti-COX IV 1:3000 (an enzyme localized in the inner mitochondrial membrane 
used as a mitochondrial loading control; Cell Signaling Technology Inc, Danvers, MA, USA), 
rabbit polyclonal anti-Bax 1:500, goat polyclonal anti-Smac/DIABLO 1:200, goat polyclonal 
anti-actin 1:3000 (Santa Cruz Biotechnology Inc, Santa Cruz, CA, USA), goat polyclonal t-
Bid and total Bid 1:1000 (R&D Systems Inc, Minneapolis, MN, USA). Membranes were then 
washed three times with TBS-T for 10
 
min and subsequently incubated for 1 h with the 
appropriate secondary antibody conjugated to horseradish peroxidase (Santa Cruz 
Biotechnology Inc, Santa Cruz, CA, USA). Bands were visualized with chemiluminescence 
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(Pierce ECL Western Blotting Substrate, Pierce Biotechnology Inc, Rockford, IL, USA) and 
analysed with the Image J software (NIH, Bethesda, MA, USA). 
Statistical analysis 
All values are expressed as mean ± SEM for the number of samples indicated in the 
legends of figures. Comparisons between groups were assessed using ANOVA followed if 
necessary by Student’s t-test. Statistical significance was defined as a value of p<0.05.  
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RESULTS 
Effect of PTD-BIR3/RING on myocardial infarct size 
As shown in table 1, animal body weights and sizes of area at risk were similar among 
groups. As illustrated in figure 2, PTD-BIR3/RING significantly reduced infarct size as 
compared to Control when administered 5 min before and 30 min after the onset of 
reperfusion (23±2% vs 41±4% and 27±4% vs 41±3%, respectively). Similar reduction in 
infarct size was observed when PTD-BIR3/RING was administered prior to ischemia (28±1% 
vs 44±3%). 
Histology 
In contrast with the major difference in infarct size between the two groups, histological 
analysis only revealed moderate different patterns of lesions within the infarct as shown in 
figure 3. In control mice, the main focus of infarction demonstrated a homogenous pattern of 
cell death whereas in PTD-BIR3/RING treated mice, it was less homogenous and made of 
patchy foci of cell death. 
Caspase activities  
In control mice, caspase-3, caspase-8 and caspase-9 activities were increased at 3 h of 
reperfusion as illustrated in figure 4. When PTD-BIR3/RING was administered at 30 min of 
reperfusion, these increases were significantly blunted by PTD-BIR3/RING. After 24 h of 
reperfusion, all caspase activities were similar in the PTD-BIR-3/RING and control mice and 
these values were similar to those observed in mice that did not suffer ischemia-reperfusion 
(61±14, 69±7 and 7±1 µM AFC/h/mg protein for caspase-3, -8 and -9, respectively). 
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Western blot analysis 
As illustrated in figure 5, the phosphorylated Bad/Bad ratio was significantly increased in 
PTD-BIR3/RING treated mice (+342 %) as compared to Control. Concomitantly with 
inhibition of caspase-8 activity, we observed that the ratio of truncated Bid to total Bid was 
significantly reduced by PTD-BIR3/RING (-41 %). In addition, as several pro-apoptotic 
proteins are known to translocate between the cytosol and the mitochondria, we analysed their 
subcellular location. Analysis of the cytosolic and mitochondrial fractions revealed that PTD-
BIR3/RING significantly increased the Bax cytosolic to mitochondrial ratio as compared to 
Control. Finally, Smac/DIABLO cytosolic to mitochondrial ratios were similar between the 
two groups. 
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DISCUSSION 
The present study demonstrates that the administration of BIR3/RING using the protein 
transduction domain (PTD) of the TAT-fusion system, i.e., PTD-BIR3/RING up to 30 min 
during reperfusion significantly reduces myocardial infarct size in mice subjected to 30 min 
coronary artery occlusion. The novel finding is that the previously ischemic myocardium can 
be salvaged by pharmacologically mimicking the effects of XIAP during reperfusion. This is 
consistent with a previous report demonstrating that overexpression of the endogenous 
inhibitor IAP-2 significantly reduces myocardial infarct size and apoptosis (25). The 
beneficial effect observed in our study was achieved through inhibiting caspase-mediated cell 
death pathways. Besides inhibition of caspase-3 and -9, PTD-BIR3/RING also blunted the 
increase in caspase-8 activity. This was associated with the reduction of ischemia-induced 
truncation of Bid, a target of caspase-8, and inactivation of key players of the apoptotic 
mitochondrial pathway such as the Bcl-2 family members Bax and Bad. Interestingly, PTD-
BIR3/RING administered prior to ischemia or reperfusion did not afford a higher degree of 
protection than when administered at reperfusion suggesting that the cardioprotective effect of 
PTD-BIR3/RING is mainly related due to the interruption of deleterious signaling pathways 
that are activated during reperfusion. 
Among numerous proteins that are known to regulate caspase activity, XIAP is the most 
potent inhibitor of apoptosis (26). The PTD peptide of the HIV1-TAT can enter into the cells 
efficiently when added exogenously and allows cellular delivery of macromolecules. In the 
present study, PTD-BIR3/RING had kept its main biological activity as its administration 
abolished the increases in caspase-3 and caspase-9 activities during reperfusion. More 
importantly, it has been demonstrated, using purified recombinant proteins, that the BIR3 
domain is the minimal region of XIAP needed for potent caspase-9 inhibition (17) and that the 
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RING domain of XIAP is essential for destruction of caspase-3 through the proteasome (18, 
21). Caspase-9 is an initiator caspase that is in the first wave of activation when apoptosis is 
triggered. Caspase-3 is activated through the action of initiator caspases and its activation 
results in irreversible cell damage and death (27). Histological analysis revealed differential 
tissular aspects as, in contrast to control mice, the main focus of infarct in the PTD-
BIR3/RING treated mice was less homogeneous suggesting patchy areas of salvaged tissues. 
It should also be considered that Smac/DIABLO is released by the mitochondria into the 
cytosol where it binds to IAPs, displacing caspases and thus enhancing the apoptotic signal 
(28). In our experimental conditions, we observed that the cytosolic to mitochondrial ratio of 
Smac/DIABLO was unchanged in PTD-BIR3/RING treated mice. We cannot exclude that 
part of PTD-BIR3/RING was inhibited by Smac/DIABLO. Nevertheless, the effects observed 
in PTD-BIR3/RING treated animals indicate that the amount of administered PTD-
BIR3/RING override the endogenous inhibitory effect of Smac/DIABLO. 
We also demonstrated for the first time that PTD-BIR3/RING inhibits caspase-8 activity. 
This result is of great importance as caspase-8 is at crossroads between the extrinsic and 
intrinsic apoptosis pathways (27) and plays multiple roles in apoptosis (29). Besides being an 
initiator caspase of the death-receptors pathway, caspase-8 exhibits a direct protease activity 
in the nucleus and plays an amplificatory role of the mitochondrial apoptotic pathway by 
cleavage and activation of the Bcl-2-related pro-apoptotic molecule Bid. Truncated Bid 
activates another member of the Bcl-2 family, Bax, which translocates into the outer 
mitochondrial membrane and participates to the pore formation. The resulting release of 
apoptogenic factors activates effector caspases. Consistent with its protective effect, PTD-
BIR3/RING induced a significant decrease in truncated Bid and reduced the translocation of 
Bax from the cytosol to the mitochondria as demonstrated by the reduction in Bax cytosolic to 
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mitochondrial ratio. PTD-BIR3/TING was also responsible for an increase in the 
phosphorylation of Bad favouring its cytosolic sequestration. 
Although we did not specifically investigate the mechanisms of caspase-8 inhibition by 
PTD-BIR3/RING, some hypotheses can be raised. CARPs (caspase-8 and -10 associated 
RING proteins) represent a family of anti-apoptotic proteins that specifically bind to and 
regulate DED (death effector domain) caspases such as caspase-8. Their RING domain 
possesses a high homology with the IAP family and exhibits a E3 ligase activity which may 
contribute to the ubiquitin-mediated proteolysis of DED caspases (30). It has also been 
demonstrated in epithelial cancer cell lines that activated caspase-3 cleaves and activates 
caspase-8 (31). One could therefore speculate that inhibition of caspase-8 activity by PTD-
BIR3/RING may involve the E3 ubiquitin ligase activity of its RING domain or an indirect 
inhibition through caspase-3 inhibition. However, investigation of these issues was beyond 
the scope of this study. 
It is also important to emphasize that the beneficial effects of PTD-BIR3/RING were still 
observed when administered up to 30 min after the onset of reperfusion. To date, the so-called 
postconditioning or the administration of pharmacological agents have to be started within the 
very first minutes of reperfusion to be efficient. Indeed, starting administration of the 
adenosine agonist agent AMP579 after 10 min of reperfusion or postconditioning after the 
first minutes of reperfusion is too late (11, 12). Such delayed cardioprotective effect of PTD-
BIR3/RING is rather similar to that reported with other pharmacological strategies (32, 33). 
Finally, previous studies have also reported the beneficial effects of several caspase inhibitors 
but the administration of the blockers was started before the onset of reperfusion (34-37).  
In conclusion, this study demonstrates that the administration of PTD-BIR3/RING reduces 
myocardial infarct size even when administered during reperfusion. PTD-BIR3/RING exerts 
  
15 
its cardioprotective effect through the interruption of caspase activation by pharmacologically 
mimicking endogenous XIAP. 
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LEGEND OF FIGURES 
Figure 1 
Experimental protocols (CAO: coronary artery occlusion; CAR: coronary artery reperfusion) 
in mice receiving either vehicle (Control) or PTD-BIR3/RING (BIR, 0.8 µg/g). The arrows 
indicate the timing of PTD-BIR3/RING administration. 
Figure 2 
Individual and averaged values of infarct size expressed as percentage of the area at risk 
(AAR) measured at 24 h of coronary artery reperfusion (CAR) after 30 min coronary artery 
occlusion (CAO) in Control (C) and PTD-BIR3/RING-treated mice (BIR, 0.8µg/g). *, p<0.05 
vs corresponding Control. 
Figure 3 
Histological analysis with H&E staining in control mice (panels A-C) and PTD-BIR3/RING 
treated mice (panels D-F). 
A: At low magnification the main focus of infarction is quite homogeneous and made of dead 
cells. On the left of the figure, note the viable area of the myocardium (bar = 100µm); B: 
Higher magnification clearly shows the homogeneous pattern of cell death within the main 
infarct focus (bar = 50 µm); C: At the periphery of the main focus, note the patchy pattern 
mode of individual or grouped cells (bar = 50 µm); D: At low magnification, the main focus 
of infarction is less homogeneous and made of patchy areas of cell death (bar = 100µm). E: 
Higher magnification confirms the panel D (bar = 50 µm). F: At the periphery of the main 
infarct focus, note the patchy pattern of cell death (bar = 50 µm). 
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Figure 4 
Caspase activities in Control (open bars) and PTD-BIR3/RING-treated mice (shaded bars) at 
30 min of reperfusion. Measurements were performed at 1 h, 3 h and 24 h of coronary artery 
reperfusion (CAR). *, p<0.05 vs corresponding Control. 
Figure 5 
Representative Western blots showing that PTD-BIR3/RING (BIR, shaded bars) administered 
at 30 min of reperfusion induced significant increase of phosphorylated Bad/Bad, Bax 
cytosolic to mitochondrial ratio as well as reduction in Bid truncation as compared to Control 
(C, open bars). Smac/DIABLO cytosolic to mitochondrial ratio was similar between PTD-
BIR3/RING and Control. *, p< 0.05 vs corresponding Control. 
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Table 1. Body weights and areas at risk
n BW (g) AAR (% LV)
5 min before CAO
Control 5 25 ± 2 37 ± 3
PTD-BIR3/RING 4 24 ± 1 38 ± 4
5 min before CAR
Control 6 26 ± 3 40 ± 3
PTD-BIR3/RING 6 23 ± 1 36 ± 3
30 min CAR
Control 9 26 ± 3 39 ± 3
9 27 ± 3 45 ± 3
PTD-BIR3/RING
Values are mean ± s.e.m.
AAR: area at risk; BW: body weight; CAO: coronary artery occlusion
CAR: coronary artery reperfusion; LV: left ventricle.
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